<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="72">
  <stage>Registered</stage>
  <submitdate>25/07/2005</submitdate>
  <approvaldate>5/08/2005</approvaldate>
  <actrnumber>ACTRN12605000078651</actrnumber>
  <trial_identification>
    <studytitle>A randomized phase III study to evaluate the effects of Oxpentifyllene as an add on therapy for boys with duchenne muscular dystrophy in improving muscle strength and function.</studytitle>
    <scientifictitle>A randomized phase III study to evaluate the effects of Oxpentifyllene as an add on therapy for boys with duchenne muscular dystrophy in improving muscle strength and function.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Duchenne muscular dystrophy</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>12-month trial of steroids plus Oxpentifylline as an add on treatment</interventions>
    <comparator>Steroids + placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Muscle strength</outcome>
      <timepoint>Evaluated at the start of the trial (prior to the commencement of treatment drug or placebo), 1 month, 4 months, 8 months and 12 months after starting on the trial.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment for changes in inflammation and muscle fibrosis.</outcome>
      <timepoint>At the start of the trial, and after the conclusion of the trial (12 months after starting Oxpentifylline or placebo).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Duchenne muscular dystrophy, ambulant, stable dose of steroids for 12 months.</inclusivecriteria>
    <inclusiveminage>7</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomised by coordinating centre pharmacy</concealment>
    <sequence>Randomisation will be accomplished by pre-generating a database of randomly permuted balanced blocks.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/02/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>64</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Children's Hospital at Westmead</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Institute for Neuromuscular Research</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Cooperative International Neuromuscular Research Group</sponsorname>
      <sponsoraddress />
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Oxpentifylline is being trialled as an add on drug to steroids - at present the only known med to positively influence DMD. It is thought that it may reduce some of the secondary problems in muscles such as fibrosis and inflammation.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sian Rudge</name>
      <address>Clinical Sciences
The Children's Hospital at Westmead
Locked Bag 4001
Westmead NSW 2145</address>
      <phone>+61 2 98451229</phone>
      <fax>+61 2 98451317</fax>
      <email>sianr@chw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sian Rudge</name>
      <address>Clinical Sciences
The Children's Hospital at Westmead
Locked Bag 4001
Westmead NSW 2145</address>
      <phone>+61 2 98451229</phone>
      <fax>+61 2 98451317</fax>
      <email>sianr@chw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>